{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T22:26:39Z","timestamp":1789683999431,"version":"4.0.1"},"reference-count":87,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T00:00:00Z","timestamp":1762300800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Immunoglobulin M (IgM) antibodies are gaining renewed attention as next-generation platforms for cancer immunotherapy. Compared with IgG, IgM exhibits distinct biological advantages, including higher avidity from multivalent binding, potent complement activation, and enhanced recognition of heterogeneous tumor antigens within immunosuppressive microenvironments. These attributes position IgM as a promising candidate for solid tumor therapy, despite the absence of currently approved IgM-based therapeutics. Recent advances in genetic engineering, antibody design, and protein manufacturing have enabled the generation of diverse IgM formats\u2014ranging from monoclonal and bispecific constructs to engineered IgM derivatives\u2014demonstrating substantial antitumor potential in preclinical and early translational studies. Nonetheless, clinical development faces persistent challenges, including short serum half-life, restricted tumor penetration, structural and biophysical complexity, and scalability of production. In this review, we discuss the structure and biology of IgM, highlight progress in developing novel IgM-based antibody formats for solid tumors, and critically examine the key translational barriers and future opportunities. Together, these insights underscore the therapeutic promise of IgM and chart a path toward its integration into the next generation of antibody-based cancer immunotherapies.<\/jats:p>","DOI":"10.3389\/fimmu.2025.1712344","type":"journal-article","created":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T06:29:05Z","timestamp":1762324145000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Harnessing IgM for solid tumor therapy: biology, engineering advances, and translational challenges"],"prefix":"10.3389","volume":"16","author":[{"given":"Yuhui","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuhan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yinuo","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shimei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lifang","family":"Bu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenjing","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinlin","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,11,5]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1186\/s12929-024-00996-w","article-title":"Therapeutic antibodies for the prevention and treatment of cancer","volume":"31","author":"Kumar","year":"2024","journal-title":"J Biomed Sci"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.3390\/ijms26167724","article-title":"Low antibody dosing in cancer therapy: targeted cytotoxicity combined with anti-tumour immunostimulation","volume":"26","author":"Seledtsov","year":"2025","journal-title":"Int J Mol Sci"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2024.102826","article-title":"Targeting HER2 in solid tumors: Unveiling the structure and novel epitopes","volume":"130","author":"Liu","year":"2024","journal-title":"Cancer Treat Rev"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1038\/s41418-025-01582-9","article-title":"TRIM24-mediated K27-linked ubiquitination of ULK1 alleviates energy stress-induced autophagy and promote prostate cancer growth in the context of SPOP mutation","author":"Chen","year":"2025","journal-title":"Cell Death Differ"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.7150\/thno.98178","article-title":"Trop2-targeted therapies in solid tumors: advances and future directions","volume":"14","author":"Liu","year":"2024","journal-title":"Theranostics"},{"key":"B6","article-title":"Influence of affinity and antigen density on antibody localization in a modifiable tumor targeting model","volume":"60","author":"Zuckier","year":"2000","journal-title":"Cancer Res"},{"key":"B7","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1007\/978-1-4939-8958-4_3","article-title":"IgM natural autoantibodies in physiology and the treatment of disease","volume":"1904","author":"Fereidan-Esfahani","year":"2019","journal-title":"Methods Mol Biol (Clifton N.J.)"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.Mct-20-1132","article-title":"Multimeric anti-DR5 igM agonist antibody IGM-8444 is a potent inducer of cancer cell apoptosis and synergizes with chemotherapy and BCL-2 inhibitor ABT-199","volume":"20","author":"Wang","year":"2021","journal-title":"Mol Cancer Ther"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.3390\/antib9040053","article-title":"Structure, Function, and Therapeutic Use of IgM Antibodies","volume":"9","author":"Keyt","year":"2020","journal-title":"Antibodies (Basel)"},{"key":"B10","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1038\/s41568-024-00690-x","article-title":"Cancer therapy with antibodies","volume":"24","author":"Paul","year":"2024","journal-title":"Nat Rev Cancer"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.3389\/fgene.2021.827161","article-title":"Immunoglobulin classification based on FC* and GC* Features","volume":"12","author":"Wan","year":"2021","journal-title":"Front Genet"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2009.09.046","article-title":"Structure and function of immunoglobulins","volume":"125","author":"Schroeder","year":"2010","journal-title":"J Allergy Clin Immunol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1038\/nri1266","article-title":"Human antibody-Fc receptor interactions illuminated by crystal structures","volume":"4","author":"JM","year":"2004","journal-title":"Nat Rev Immunol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1038\/264415a0","article-title":"Crystallographic structure studies of an IgG molecule and an Fc fragment","volume":"264","author":"Robert","year":"1976","journal-title":"Nature"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.052150899","article-title":"& K, H. Immunoglobulin heavy chain constant regions regulate immunity and tolerance to idiotypes of antibody variable regions","volume":"99","author":"SK","year":"2002","journal-title":"Proc Natl Acad Sci United States America"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1007\/s40259-025-00720-6","article-title":"Understanding igM structure and biology to engineer new antibody therapeutics","volume":"39","author":"Buchner","year":"2025","journal-title":"BioDrugs"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-immunol-101320-123742","article-title":"Molecular mechanisms of multimeric assembly of igM and igA","volume":"40","author":"Matsumoto","year":"2022","journal-title":"Annu Rev Immunol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.3390\/ijms222312776","article-title":"3D structures of igA, igM, and components","volume":"22","author":"Pan","year":"2021","journal-title":"Int J Mol Sci"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1701797114","article-title":"A peptide extension dictates IgM assembly","volume":"114","author":"Pasalic","year":"2017","journal-title":"Proc Natl Acad Sci U.S.A"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1126\/science.abo3923","article-title":"Cryo-EM structure of the human IgM B cell receptor","volume":"377","author":"Su","year":"2022","journal-title":"Science"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1126\/science.aaz5425","article-title":"Structural insights into immunoglobulin M","volume":"367","author":"Li","year":"2020","journal-title":"Science"},{"key":"B22","doi-asserted-by":"publisher","first-page":"eaau1199","DOI":"10.1126\/sciadv.aau1199","article-title":"The IgM pentamer is an asymmetric pentagon with an open groove that binds the AIM protein","volume":"4","author":"Hiramoto","year":"2018","journal-title":"Sci Adv"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/j.str.2021.01.002","article-title":"Structure of the human secretory immunoglobulin M core","volume":"29","author":"Nikit","year":"2021","journal-title":"Structure (London England: 1993)"},{"key":"B24","doi-asserted-by":"publisher","first-page":"6314","DOI":"10.1038\/s41467-022-34090-2","article-title":"Cryomicroscopy reveals the structural basis for a flexible hinge motion in the immunoglobulin M pentamer","volume":"13","author":"Chen","year":"2022","journal-title":"Nat Commun"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0903805106","article-title":"The human IgM pentamer is a mushroom-shaped molecule with a flexural bias","volume":"106","author":"Czajkowsky","year":"2009","journal-title":"Proc Natl Acad Sci United States America"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-023-05835-w","article-title":"Immunoglobulin M perception by fc\u03bcR","volume":"615","author":"Li","year":"2023","journal-title":"Nature"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1038\/s41594-023-00985-x","article-title":"Structural basis for Fc receptor recognition of immunoglobulin M","volume":"30","author":"Chen","year":"2023","journal-title":"Nat Struct Mol Biol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1901841116","article-title":"Insights into IgM-mediated complement activation based on in situ structures of IgM-C1-C4b","volume":"116","author":"Sharp","year":"2019","journal-title":"Proc Natl Acad Sci United States America"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1109831108","article-title":"Requirement for complement in antibody responses is not explained by the classic pathway activator IgM","volume":"108","author":"Rutemark","year":"2011","journal-title":"Proc Natl Acad Sci U.S.A"},{"key":"B30","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1186\/s12951-025-03213-4","article-title":"IgM has a better relative distribution in inflammation sites and tumor tissues than IgG","volume":"23","author":"Aldayel","year":"2025","journal-title":"J Nanobiotechnology"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1038\/nri2849","article-title":"The importance of natural IgM: scavenger, protector and regulator","volume":"10","author":"Ehrenstein","year":"2010","journal-title":"Nat Rev Immunol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.14670\/hh-20.927","article-title":"The \u201cearly birds\u201d: natural IgM antibodies and immune surveillance","volume":"20","author":"Vollmers","year":"2005","journal-title":"Histol histopathology"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1007\/bf01741747","article-title":"Complement-dependent lysis of tumor cells by a baboon IgM antibody to a tumor-associated antigen","volume":"34","author":"Hunt","year":"1992","journal-title":"Cancer immunology immunotherapy: CII"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.93.9.4498","article-title":"Normal human serum contains a natural IgM antibody cytotoxic for human neuroblastoma cells","volume":"93","author":"Ollert","year":"1996","journal-title":"Proc Natl Acad Sci U.S.A"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1358\/mf.2005.27.3.890876","article-title":"Death by stress: natural IgM-induced apoptosis","volume":"27","author":"Vollmers","year":"2005","journal-title":"Methods findings Exp Clin Pharmacol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24065728","article-title":"Physiological and pathophysiological roles of igM fc receptor (Fc\u00b5R) isoforms","volume":"24","author":"Kubagawa","year":"2023","journal-title":"Int J Mol Sci"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1016\/0165-2478(94)90106-6","article-title":"Binding of natural human IgM auto-antibodies to human tumor cell lines and stimulated normal T lymphocytes","volume":"39","author":"Bohn","year":"1994","journal-title":"Immunol Lett"},{"key":"B38","first-page":"75","article-title":"Suppression of Ehrlich subcutaneous solid tumor growth by immunization with ganglioside GT1b of its origin, its IgM antibody or anti-idiotype antibody","volume":"20","author":"Saha","year":"2001","journal-title":"J Exp Clin Cancer Res"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.3892\/or.2015.4095","article-title":"Natural and adaptive IgM antibodies in the recognition of tumor-associated antigens of breast cancer (Review)","volume":"34","author":"D\u00edaz-Zaragoza","year":"2015","journal-title":"Oncol Rep"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1165\/rcmb.2018-0159OC","article-title":"Immune surveillance by natural igM is required for early neoantigen recognition and initiation of adaptive immunity","volume":"59","author":"Atif","year":"2018","journal-title":"Am J Respir Cell Mol Biol"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbamcr.2022.119295","article-title":"An IgM monoclonal antibody against domain 1 of CD147 induces non-canonical RIPK-independent necroptosis in a cell type specific manner in hepatocellular carcinoma cells","volume":"1869","author":"Pomlok","year":"2022","journal-title":"Biochim Biophys Acta Mol Cell Res"},{"key":"B42","doi-asserted-by":"publisher","first-page":"e61239","DOI":"10.1371\/journal.pone.0061239","article-title":"Simultaneous binding of the anti-cancer IgM monoclonal antibody PAT-SM6 to low density lipoproteins and GRP78","volume":"8","author":"Kaufmann","year":"2013","journal-title":"PloS One"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1097\/CMR.0b013e328362cbc8","article-title":"Early development of PAT-SM6 for the treatment of melanoma","volume":"23","author":"Hensel","year":"2013","journal-title":"Melanoma Res"},{"key":"B44","doi-asserted-by":"publisher","first-page":"e44927","DOI":"10.1371\/journal.pone.0044927","article-title":"The anti-cancer IgM monoclonal antibody PAT-SM6 binds with high avidity to the unfolded protein response regulator GRP78","volume":"7","author":"Pizzo","year":"2012","journal-title":"PloS One"},{"key":"B45","doi-asserted-by":"publisher","first-page":"e63414","DOI":"10.1371\/journal.pone.0063414","article-title":"The natural human IgM antibody PAT-SM6 induces apoptosis in primary human multiple myeloma cells by targeting heat shock protein GRP78","volume":"8","author":"Han","year":"2013","journal-title":"PloS One"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2014.117945","article-title":"GRP78-directed immunotherapy in relapsed or refractory multiple myeloma - results from a phase 1 trial with the monoclonal immunoglobulin M antibody PAT-SM6","volume":"100","author":"Rasche","year":"2015","journal-title":"Haematologica"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-06-0399","article-title":"The human IgM antibody SAM-6 induces tumor-specific apoptosis with oxidized low-density lipoprotein","volume":"6","author":"Brandlein","year":"2007","journal-title":"Mol Cancer Ther"},{"key":"B48","doi-asserted-by":"publisher","first-page":"e0291568","DOI":"10.1371\/journal.pone.0291568","article-title":"Understanding the biosynthesis of human IgM SAM-6 through a combinatorial expression of mutant subunits that affect product assembly and secretion","volume":"19","author":"Fugmann","year":"2024","journal-title":"PloS One"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1172\/jci4105","article-title":"The cell-surface heparan sulfate proteoglycan glypican-1 regulates growth factor action in pancreatic carcinoma cells and is overexpressed in human pancreatic cancer","volume":"102","author":"Kleeff","year":"1998","journal-title":"J Clin Invest"},{"key":"B50","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1186\/s12967-023-04745-9","article-title":"A novel complement-fixing IgM antibody targeting GPC1 as a useful immunotherapeutic strategy for the treatment of pancreatic ductal adenocarcinoma","volume":"21","author":"Busato","year":"2023","journal-title":"J Transl Med"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-131650","article-title":"High avidity igM-based CD20xCD3 bispecific antibody (IGM-2323) for enhanced T-cell dependent killing with minimal cytokine release","volume":"134","author":"Baliga","year":"2019","journal-title":"Blood"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2021-153355","article-title":"A phase 1 dose escalation study of igm-2323, a novel anti-CD20 x anti-CD3 igM T cell engager (TCE) in patients with advanced B-cell Malignancies","volume":"138","author":"Budde","year":"2021","journal-title":"Blood"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-159205","article-title":"Igm-2644, a novel CD38xCD3 bispecific igM T cell engager demonstrates potent efficacy on myeloma cells with an improved preclinical safety profile","volume":"140","author":"Li","year":"2022","journal-title":"Blood"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-24-0937","article-title":"IGM-7354, an immunocytokine with IL15 fused to an anti-PD-L1 igM, induces NK and CD8+ T cell-mediated cytotoxicity of PD-L1-positive tumor cells","volume":"13","author":"Desbois","year":"2025","journal-title":"Cancer Immunol Res"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2023.101297","article-title":"GRP78-CAR T cell effector function against solid and brain tumors is controlled by GRP78 expression on T cells","volume":"4","author":"Ibanez","year":"2023","journal-title":"Cell Rep Med"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2020.10.055","article-title":"Cell surface GRP78: An emerging imaging marker and therapeutic target for cancer","volume":"328","author":"Farshbaf","year":"2020","journal-title":"J Control Release"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-15-3111","article-title":"A GRP78-directed monoclonal antibody recaptures response in refractory multiple myeloma with extramedullary involvement","volume":"22","author":"Rasche","year":"2016","journal-title":"Clin Cancer Res"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-025-01207-9","article-title":"Fifty years of monoclonals: the past, present and future of antibody therapeutics","volume":"25","author":"Chan","year":"2025","journal-title":"Nat Rev Immunol"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-20-3770","article-title":"Bispecific immunomodulatory antibodies for cancer immunotherapy","volume":"27","author":"Blanco","year":"2021","journal-title":"Clin Cancer Res"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics14112442","article-title":"Bispecific antibodies: A novel approach for the treatment of solid tumors","volume":"14","author":"Liguori","year":"2022","journal-title":"Pharmaceutics"},{"key":"B61","doi-asserted-by":"publisher","first-page":"105250","DOI":"10.1016\/j.exphem.2025.105250","article-title":"An engineered IgM antibody targeting CD20 has enhanced complement-dependent cytotoxicity compared with an IgG","volume":"152","author":"Hart","year":"2025","journal-title":"Exp Hematol"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.00945","article-title":"Functional roles of the igM fc receptor in the immune system","volume":"10","author":"Hiromi","year":"2019","journal-title":"Front Immunol"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1080\/19420862.2024.2394229","article-title":"Developability considerations for bispecific and multispecific antibodies","volume":"16","author":"Amash","year":"2024","journal-title":"MAbs"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1080\/19420862.2024.2403156","article-title":"A comparative study of the developability of full-length antibodies, fragments, and bispecific formats reveals higher stability risks for engineered constructs","volume":"16","author":"Condado-Morales","year":"2024","journal-title":"MAbs"},{"key":"B65","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1007\/s13238-017-0457-8","article-title":"Current progress in innovative engineered antibodies","volume":"9","author":"Strohl","year":"2018","journal-title":"Protein Cell"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1007\/BF00199991","article-title":"In vivo antitumor effect of methotrexate conjugated to a monoclonal IgM antibody specific for stage-specific embryonic antigen-1, on MH-15 mouse teratocarcinoma","volume":"29","author":"Persiani","year":"1989","journal-title":"Cancer Immunol Immunother"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1126\/science.2897133","article-title":"Radioimmunotherapy with alpha-particle-emitting immunoconjugates","volume":"240","author":"Macklis","year":"1988","journal-title":"Science"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1016\/j.ab.2019.113385","article-title":"Chemoenzymatic glycan labelling as a platform for site-specific IgM-antibody drug conjugates","volume":"584","author":"Moh","year":"2019","journal-title":"Analytical Biochem"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1258700","article-title":"Conditional activation of an anti-IgM antibody-drug conjugate for precise B cell lymphoma targeting","volume":"14","author":"Schoenfeld","year":"2023","journal-title":"Front Immunol"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1172\/JCI104987","article-title":"Metabolism of human gamma macroglobulins","volume":"43","author":"Barth","year":"1964","journal-title":"J Clin Invest"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1002\/eji.1830180221","article-title":"The half-lives of serum immunoglobulins in adult mice","volume":"18","author":"Vieira","year":"1988","journal-title":"Eur J Immunol"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1177\/1756286421997381","article-title":"The importance of FcRn in neuro-immunotherapies: From IgG catabolism, FCGRT gene polymorphisms, IVIg dosing and efficiency to specific FcRn inhibitors","volume":"14","author":"Dalakas","year":"2021","journal-title":"Ther Adv Neurol Disord"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1111\/pbi.14552","article-title":"Modification of Fc-fusion protein structures to enhance efficacy of cancer vaccine in plant expression system","volume":"23","author":"Lim","year":"2025","journal-title":"Plant Biotechnol J"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.2147\/DMSO.S421527","article-title":"Research advances in fusion protein-based drugs for diabetes treatment","volume":"17","author":"Deng","year":"2024","journal-title":"Diabetes Metab Syndr Obes"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1080\/19420862.2018.1490119","article-title":"Extending human IgG half-life using structure-guided design","volume":"10","author":"Booth","year":"2018","journal-title":"MAbs"},{"key":"B76","doi-asserted-by":"publisher","first-page":"2007","DOI":"10.1038\/s41467-024-46321-9","article-title":"Human IgG Fc-engineering for enhanced plasma half-life, mucosal distribution and killing of cancer cells and bacteria","volume":"15","author":"Foss","year":"2024","journal-title":"Nat Commun"},{"key":"B77","doi-asserted-by":"publisher","first-page":"e2301777","DOI":"10.1002\/advs.202301777","article-title":"Interplay between liposomes and igM: principles, challenges, and opportunities","volume":"10","author":"Wang","year":"2023","journal-title":"Adv Sci (Weinh)"},{"key":"B78","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1111\/imr.12350","article-title":"Mouse and human FcR effector functions","volume":"268","author":"Bruhns","year":"2015","journal-title":"Immunol Rev"},{"key":"B79","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1038\/s41568-023-00637-8","article-title":"Fcgamma receptors and immunomodulatory antibodies in cancer","volume":"24","author":"Galvez-Cancino","year":"2024","journal-title":"Nat Rev Cancer"},{"key":"B80","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1038\/nri2206","article-title":"Fcgamma receptors as regulators of immune responses","volume":"8","author":"Nimmerjahn","year":"2008","journal-title":"Nat Rev Immunol"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2020.107753","article-title":"Tumor microenvironment as a therapeutic target in cancer","volume":"221","author":"Xiao","year":"2021","journal-title":"Pharmacol Ther"},{"key":"B82","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1038\/s41392-020-00280-x","article-title":"The updated landscape of tumor microenvironment and drug repurposing","volume":"5","author":"Jin","year":"2020","journal-title":"Signal Transduct Target Ther"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1016\/j.smim.2022.101642","article-title":"Complement activation in cancer: Effects on tumor-associated myeloid cells and immunosuppression","volume":"60","author":"Magrini","year":"2022","journal-title":"Semin Immunol"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1080\/19420862.2023.2248671","article-title":"A machine learning strategy for the identification of key in silico descriptors and prediction models for IgG monoclonal antibody developability properties","volume":"15","author":"Waight","year":"2023","journal-title":"MAbs"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1002\/jps.24430","article-title":"Developability assessment during the selection of novel therapeutic antibodies","volume":"104","author":"Jarasch","year":"2015","journal-title":"J Pharm Sci"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1080\/19420862.2020.1743053","article-title":"Predicting antibody developability profiles through early stage discovery screening","volume":"12","author":"Bailly","year":"2020","journal-title":"mAbs"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1039\/c9sc04722k","article-title":"Not all therapeutic antibody isotypes are equal: the case of IgM versus IgG in Pertuzumab and Trastuzumab","volume":"11","author":"Samsudin","year":"2020","journal-title":"Chem Sci"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1712344\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T06:29:06Z","timestamp":1762324146000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1712344\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,5]]},"references-count":87,"alternative-id":["10.3389\/fimmu.2025.1712344"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1712344","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,5]]},"article-number":"1712344"}}